564 Results (Page 2 of 23)
Japan Markets Research Reports
Japan Home Infusion Therapy Market
The Japan Home Infusion Therapy Market was valued at $2235.2 Mn in 2023 and is predicted to grow at a CAGR of 8.6% from 2023 to 2030, to $3982.3 Mn by 2030. The key drivers of the market include rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. The prominent players of the Japan Home Infusion Therapy Market are Terumo Corporation, Nipro Corporation, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others.
Japan Hepatitis A Therapeutics Market Analysis
The Japan Hepatitis A Therapeutics Market was valued at $45.82 Mn in 2023 and is predicted to grow at a CAGR of 2.7% from 2023 to 2030 to $55.22 Mn by 2030. The market's growth is fuelled by an increase in the prevalence of Hepatitis A, evidenced by 162 confirmed cases and the inaugural report of a death from an acute hepatitis variant as of 2023. Leading companies in this sector include Takeda and GlaxoSmithKline (GSK), among others.
Japan Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis
Japan Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming.Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc
Japan Pharmaceutical Market Analysis
This report presents a strategic analysis of the Japan Pharmaceutical Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Japan Pharmaceutical Market, offering unmatched value, accuracy and expert insights.
Japan Mucopolysaccharidosis I (MPS-I) Therapeutics Market Analysis
Japan Mucopolysaccharidosis I (MPS-I) therapeutics market is projected to grow from $0.15 Bn in 2022 to $0.25 Bn by 2030, registering a CAGR of 6.4% during the forecast period of 2022-30. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in this market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
Japan Clinical Trials Support Service Market Analysis
This report presents a strategic analysis of the Japan Clinical Trials Support Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Japan Clinical Trials Support Service Market, offering unmatched value, accuracy and expert insights.
Japan Virtual Clinical Trials Market Analysis
This report presents a strategic analysis of the Japan Virtual Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Japan Virtual Clinical Trials Market, offering unmatched value, accuracy and expert insights.
Japan Over The Counter (OTC) Analgesics Market Analysis
This report presents a strategic analysis of the Japan Over The Counter (OTC) Analgesics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Japan Over The Counter (OTC) Analgesics Market, offering unmatched value, accuracy and expert insights.
Japan Blockchain Technology in Healthcare Market Analysis
This report presents a strategic analysis of the Japan Blockchain Technology in Healthcare Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Japan Blockchain Technology in Healthcare Market, offering unmatched value, accuracy and expert insights.
Japan Artificial Intelligence (AI) in Diagnostics Market Analysis
Japan's Artificial Intelligence (AI) in the diagnostics market is projected to grow from $0.06 Bn in 2022 to $0.71 Bn by 2030, registering a CAGR of 35.5% during the forecast period of 2022-30. The market will be driven by supportive government initiatives and a heavy emphasis on technological innovations. The market is segmented by component & by diagnosis. Some of the major players include Fujifilm, Toshiba & NEC Corporation.
Japan Cold Pain Therapy Market Analysis
The Japan Cold Pain Therapy Market was valued at $137 Mn in 2022 and is predicted to grow at a CAGR of 5.7% from 2023 to 2030, to $213 Mn by 2030. The key drivers of this industry include the increasing prevalence of chronic pain disorders, growing consumer demand, and technological advancements in the therapeutics industry. The industry is primarily dominated by players such as Mentholatum, Eisai, Lion, Ossur, Romsons, Pfizer, Hisamitsu, and Johnson & Johnson among others.
Japan Cholesterol Therapeutics Market Analysis
The Japan Cholesterol Therapeutics Market is anticipated to experience a growth from $1.51 Bn in 2022 to $1.928 Bn by 2030, with a CAGR of 3.1 % during the forecast period of 2022-2030. Japan's rapidly aging population, drives an increased demand for cholesterol therapeutics, further fueled by heightened public awareness and ongoing research and development, exemplified by the recent approval of Inclisiran, a promising alternative in the field. The Japan Cholesterol Therapeutics Market encompasses various players across different segments such as AstraZeneca, Daiichi Sankyo, Eisai, Merck & Co., Novartis, Pfizer, Bayer, Sanofi, Takeda, Chugai Pharma, etc, among various others.
Japan Central Nervous System (CNS) Therapeutics Market Analysis
The Japan Central Nervous System (CNS) Therapeutics Market was valued at $13.053 Bn in 2022 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to $22.261 Bn by 2030. The key drivers of this industry include the rising prevalence of CNS disorders, supportive government initiatives, and the evolving treatment landscape. The industry is primarily dominated by players such as Abbott, Eli Lilly, Astellas, Merck, Eisai, AstraZeneca, Otsuka, and Shionogi among others.
Japan Nutritional Supplements Market Analysis
By 2030, it is anticipated that the Japan Nutrition and Supplements market will reach a value of $47.25 Bn from $23.71 Bn in 2022, growing at a CAGR of 9% during 2022-30. The market is primarily dominated by local players such as Otsuka Pharmaceutical, Taisho Pharmaceutical, Kikkoman Corporation, and Ajinomoto. The market for nutrition and supplements in Japan is primarily driven by reimbursement scenarios, increasing customer awareness, and increasing disposable incomes. The Japan nutrition and supplements market in Japan is segmented by type, product, application, and distribution channel.
Japan Electronic Health Records Market Analysis
Japan's electronic health record market size was valued at $2.26 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4% from 2022 to 2030 and will reach $3.09 Bn in 2030. Japan's EHR market growth can be attributed to the increasing adaptation of EHR by hospitals and clinics. The market is segmented by product type, application type, and end user. The key market players are Ujitsu, NEC, M3, NTT Data, and others.
Japan Dental Care Market Analysis
Japan's dental care market size is at around $2.23 Bn in 2022 and is projected to reach $3.80 Bn in 2030, exhibiting a CAGR of 6.9% during the forecast period. The largest market of dental care in Asia, driven by aesthetic sensitive needs and a growing ageing population Japan is dominated by huge corporations J. Morita Corporation, Mitsui & Co., and GC Corporation. This report is segmented by treatment type, age group, clinical setup, and by demography and provides in-depth insights into opportunities for expansion.
Japan In Vitro Fertilisation (IVF) Service Market Analysis
This report presents a strategic analysis of the Japan In Vitro Fertilisation (IVF) Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Japan In Vitro Fertilisation (IVF) Service Market, offering unmatched value, accuracy, and expert insights.
Japan Patient Support Programs (PSP) Market Analysis
This report presents a strategic analysis of the Japan Patient Support Programs (PSP) Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Japan Patient Support Programs (PSP) Market, offering unmatched value, accuracy and expert insights.
Japan Dermatological Therapeutics Market Analysis
Japan Dermatological Therapeutics Market is at around $2.56 Bn in 2023 and is projected to reach $4.71 Bn in 2030, exhibiting a CAGR of 9.1% during the forecast period. The market is being driven by an increasing aging population, a growing prevalence of dermatological disorders, and technological advancements in treatment options. The market is dominated by key players like Takeda Pharmaceutical Company Limited (JPN), Shionogi & Co., Ltd. (JPN), Eisai Co., ltd. (JPN), Almirall SA, Pfizer Inc., AbbVie Inc., Amgen Inc., Novartis AG, Johnson & Johnson, and GlaxoSmithKline Plc.
Japan Neurology Drugs Market Analysis
This report presents a strategic analysis of the Japan Neurology Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Japan Neurology Drugs Market, offering unmatched value, accuracy and expert insights.
Japan Basal Cell Carcinoma Therapeutics Market Analysis
Japan Basal Cell Carcinoma Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The most typical type of skin cancer and the most typical type of cancer overall is basal cell carcinoma (BCC). Rarely can basal cell carcinoma appear in mucous membranes; it typically appears on sun-damaged skin. The market for Basal Cell Carcinoma Therapeutics is being driven by an increase in the occurrence of skin cancers and better treatment options. The high cost of care and basal cell carcinoma's high propensity for underdiagnosis, however, are anticipated to impede the market's expansion. The high cost of care and basal cell carcinoma's high propensity for underdiagnosis, however, are anticipated to impede the market's expansion. Companies like MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others are active in the basal cell carcinoma market.
Japan Healthcare Diagnostics Market Analysis
This report presents a strategic analysis of the Japan Healthcare Diagnostics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Japan Healthcare Diagnostics Market, offering unmatched value, accuracy and expert insights.
Japan Morquio Syndrome (MPS-IV) Therapeutics Market Analysis
Japan Morquio Syndrome (MPS-IV) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. As genetic illnesses like Morquio Syndrome (MPS-IV) has become more common, there is an increasing demand for specialised drugs to treat them. Major global players in Morquio Syndrome (MPS-IV) Therapeutics Market are BioMarin, Genzyme Corporation, Shire, JCR Pharmaceuticals Co., Ltd., Sanofi, Sangamo Therapeutics, ArmaGen and GREEN CROSS CORP, Concert Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., and other players.
Japan Brain Cancer Therapeutics Market
Japan Brain Cancer Therapeutics Market valued at $143 Mn in 2022, projected to reach $332 Mn by 2030 with a 11.1% CAGR. The expected rise in instances of brain cancer, specifically glioblastoma multiforme, is projected to significantly enhance the demand for therapies aimed at treating brain cancer, thereby influencing the overall structure of the market. Top leading pharmaceutical companies presently operating in the market are Roche, Novartis, Pfizer, Merck, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Sanofi, Johnson & Johnson and Takeda.
Japan Alzheimer’s Therapeutics Market Analysis
Japan alzheimer’s therapeutics market valued at $298 Mn in 2022, projected to reach $621 Mn by 2030 with a 9.6% CAGR. The growing prevalence of Alzheimer's disease, which is fuelled by an aging population, is one major factor driving the market for drugs used to treat the condition. The leading pharmaceutical companies currently operating in the market are Eisai, Otsuka Holdings Co., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma Co., Takeda Pharmaceutical Company, Roche Holding, Novartis, Pfizer, and Lundbec.
